Sector
PharmaceuticalsOpen
₹10.24Prev. Close
₹9.76Turnover(Lac.)
₹3.19Day's High
₹10.24Day's Low
₹10.2452 Week's High
₹33.4952 Week's Low
₹8.42Book Value
₹16.35Face Value
₹10Mkt Cap (₹ Cr.)
51.3P/E
57.17EPS
0.18Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 50.1 | 50.1 | 50.1 | 40.67 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 46.58 | 68.18 | 107.78 | 118.24 |
Net Worth | 96.68 | 118.28 | 157.88 | 158.91 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 202.37 | 167.25 | 169.57 | 243.52 |
yoy growth (%) | 20.99 | -1.36 | -30.36 | 22.52 |
Raw materials | -112.35 | -94.65 | -127.94 | -171.5 |
As % of sales | 55.51 | 56.59 | 75.45 | 70.42 |
Employee costs | -14.01 | -13.41 | -11.73 | -10.27 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 29.49 | 4.73 | -16.1 | 15.23 |
Depreciation | -15.82 | -17.33 | -19.3 | -18.16 |
Tax paid | -6.71 | -1.1 | 4.07 | -2.89 |
Working capital | 9.02 | 16.64 | -30.71 | 3.77 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 20.99 | -1.36 | -30.36 | 22.52 |
Op profit growth | 57.67 | 169.55 | -73.11 | -9.21 |
EBIT growth | 144.96 | -414.59 | -115.35 | -33.57 |
Net profit growth | 527.76 | -130.15 | -197.49 | 422.36 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Omkar P Herlekar
Independent Director
Hardesh Tolani
Independent Director
Ajay Sukhwani
Independent Director
Ekta Gurnasinghani
Company Sec. & Compli. Officer
Mitti M Jain
Independent Director
Manali Bhagtani
Whole Time Director
Umesh S. Pawar
C-105 MIDC,
Mahad,
Maharashtra - 402301
Tel: 91-2145-232101/232202
Website: http://www.lasalabs.com
Email: [email protected]
Office No 56-2,
Pinnacle Busine.Park, Mahakali Caves Road,
Mumbai - 400093
Tel: 91-22-62638200
Website: www.bigshareonline.com
Email: [email protected]
Summary
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Ph...
Read More
Reports by Lasa Supergenerics Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.